Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3841136 · 5 trials · 10 indications
A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
A summary of treatment emergent adverse events (TEAEs), SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| LY3841136 Dose 1 | EXPERIMENTAL | Participants will receive LY3841136 subcutaneously (SC) |
| LY3841136 Dose 2 | EXPERIMENTAL | Participants will receive LY3841136 SC |
| LY3841136 Dose 3 | EXPERIMENTAL | Participants will receive LY3841136 SC |
| LY3841136 Dose 1 + Tirzepatide Dose 1 | EXPERIMENTAL | Participants will receive LY3841136 SC and Tirzepatide SC |
| LY3841136 Dose 2 + Tirzepatide Dose 1 | EXPERIMENTAL | Participants will receive LY3841136 SC and Tirzepatide SC |
| LY3841136 Dose 2 + Tirzepatide Dose 2 | EXPERIMENTAL | Participants will receive LY3841136 SC and Tirzepatide SC |
| LY3841136 Dose 3 + Tirzepatide Dose 3 | EXPERIMENTAL | Participants will receive LY3841136 SC and Tirzepatide SC |
| Tirzepatide Dose 3 | ACTIVE_COMPARATOR | Participants will receive Tirzepatide SC |
| LY3841136 Dose 2 + Tirzepatide Dose 3 | EXPERIMENTAL | Participants will receive LY3841136 SC and Tirzepatide SC |
| Placebo | PLACEBO_COMPARATOR | Participants will receive placebo administered SC. |
| Eloralintide (Group 1) | EXPERIMENTAL | Eloralintide administered subcutaneously (SC) in a control group of participants with normal renal function |
| Eloralintide (Groups 2 and 3) | EXPERIMENTAL | Eloralintide administered SC in groups of participants with impaired renal function |
| Eloralintide (Group 3) | EXPERIMENTAL | Eloralintide administered SC in a group of participants with end-stage renal disease (ESRD) on stable hemodialysis |
| Eloralintide (Normal Hepatic Function) | EXPERIMENTAL | Eloralintide administered subcutaneously (SC) |
| Eloralintide (Mild Hepatic Impairment) | EXPERIMENTAL | Eloralintide administered SC |
| Eloralintide (Moderate Hepatic Impairment) | EXPERIMENTAL | Eloralintide administered SC |
| Eloralintide (Severe Hepatic Impairment) | EXPERIMENTAL | Eloralintide administered SC |
| Part A: LY3841136 | EXPERIMENTAL | LY3841136 administered subcutaneously (SC) |
| Part A: Placebo | PLACEBO_COMPARATOR | Placebo administered SC |
| Part B: Tirzepatide + LY3841136-Placebo | EXPERIMENTAL | Tirzepatide administered SC along with volume-matched LY3841136-Placebo administered SC |
| Part B: LY3841136 + Tirzepatide-Placebo | EXPERIMENTAL | LY3841136 administered SC along with volume-matched Tirzepatide-Placebo administered SC |
| Part B: LY3841136 + Tirzepatide | EXPERIMENTAL | LY3841136 administered SC along with Tirzepatide administered SC |
| Part B: LY3841136-Placebo + Tirzepatide-Placebo | PLACEBO_COMPARATOR | Volume-matched LY3841136-Placebo administered SC along with volume-matched Tirzepatide-Placebo administered SC |
| LY3841136 (Part A) | EXPERIMENTAL | Single ascending doses of LY3841136 administered subcutaneously (SC). |
| LY3841136 (Part B) | EXPERIMENTAL | Multiple ascending doses of LY3841136 administered SC. |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered SC. |
| Placebo (Part B) | PLACEBO_COMPARATOR | Placebo administered SC. |
| Name | Type | Description |
|---|---|---|
| LY3841136 | DRUG | Administered SC |
| Tirzepatide | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
| LY3841136-Placebo | DRUG | Administered SC |
| Tirzepatide-Placebo | DRUG | Administered SC |
Inclusion Criteria: W8M-MC-LAA2 * Have a Body Mass Index (BMI) of ≥27 kilograms per square meter (kg/m²) * Have Type 2 Diabetes * Have a HbA1c ≥7.0 % (53 millimoles/mole (mmol/mol)) to ≤10.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more th...
Top 20 of 32 competitors
LY3841136 is an investigational small molecule being studied for weight management in obesity and overweight, including in people with type 2 diabetes. It is also being evaluated in clinical trials for hepatic insufficiency and kidney disease. The drug is in clinical development and is not approved by the FDA.
LY3841136 targets the amylin receptor, a receptor class involved in regulating appetite and food intake. By acting on this receptor, the drug is being studied for its potential to support weight management in people with obesity or overweight. It is a small molecule developed by Eli Lilly and Company.
LY3841136 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the stock exchange under the ticker LLY. The drug is an investigational small molecule in clinical development for obesity and related metabolic conditions. It is not yet approved for any use.
LY3841136 is in Phase 1 and Phase 2 clinical trials. Most completed studies are Phase 1, and an active Phase 2 trial is investigating the drug alone or with tirzepatide for weight management in adults with obesity or overweight and type 2 diabetes. The drug remains investigational.
LY3841136 has three clinical trials. NCT05295940 and NCT06297616 are completed Phase 1 studies in healthy, overweight, or obese participants. NCT06603571 is an active Phase 2 trial testing the drug with tirzepatide in obesity or overweight with type 2 diabetes. NCT07401862 is a recruiting Phase 1 study in hepatic insufficiency.
Yes, LY3841136 is also known as eloralintide. A clinical trial titled 'A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage' confirms that eloralintide is another name for this drug. Both names refer to the same investigational small molecule developed by Eli Lilly.